Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-16T17:25:11.944Z Has data issue: false hasContentIssue false

Amisulpride in schizophrenia

Published online by Cambridge University Press:  03 January 2018

S. Reid
Affiliation:
Springfield University Hospital, 61 Glenburnie Road, London SW17 7DJ
J. Turner
Affiliation:
Springfield University Hospital, 61 Glenburnie Road, London SW17 7DJ
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns
Copyright
Copyright © 1998 The Royal College of Psychiatrists 

References

Boyer, P., Lecrubier, Y., Puech, A. J., et al (1995) Treatment of negative symptoms of schizophrenia with amisulpride. British Journal of Psychiatry, 166, 6872.CrossRefGoogle ScholarPubMed
Loo, H., Poirler-Littre, M.-F., Theron, M., et al (1997) Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. British Journal of Psychiatry, 170, 1822.Google Scholar
King, D. J. (1998) Atypical antipsychotics and the negative symptoms of schizophrenia. Advances in Psychiatric Treatment, 4, 5361.Google Scholar
Speller, J. C., Barnes, T. R. E., Curs on, D. A., et al (1997) One-year, low-dose neuroleptic study of inpatients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. British Journal of Psychiatry, 171, 564568.Google Scholar
Thomas, C. S. & Lewis, S. (1998) Which atypical antipsychotic? British Journal of Psychiatry, 172, 106109.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.